New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"
In a first-in-human study at the ATMP center at Uppsala University Hospital in Sweden, the world’s first transplantation of genetically modified, hypoimmune insulin-producing cells from the islets of Langerhans has been used as a treatment. The key aspect is that the transplantation was carried out without immunosuppression. The hope is that, in the long term, this patient group could be cured of type 1 diabetes.
The American company Sana Biotechnology, which developed the hypoimmune technology, saw its stock soar after the first results were presented this week. The company’s shares rose by approximately 200 percent.
For individuals with severe type 1 diabetes, a well-established treatment involving transplantation of islets of Langerhans, a type of cell cluster containing insulin-producing cells, has been available for over 20 years. This treatment involves isolating islets of Langerhans from a deceased donor's pancreas and transplanting them into a diabetes patient with the goal of achieving normal blood sugar control and independence from insulin. However, the transplantation has required immunosuppression in the patient, which often leads to side effects and is not suitable for everyone.
https://www.lifesciencesweden.se/article/view/1138864/new_cell_therapy_raises_hope_for_curing_type_1_diabetes_never_succeeded_before
https://t.me/ToBeResearcher
Life Science Sweden
New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"
For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified insulin-producing cells that do not require immunosuppressive drugs. "A major immunological breakthrough," says Professor Per-Ola Carlsson…
1January 20, 2025 749 3
